glp 1 and gip medication Dose-equivalence reference based on pivotal GLP-1/dual-agonist trials: SURMOUNT-1 (tirzepatide/Zepbound, 72 weeks) STEP-1 (subcutaneous semaglutide/Wegovy, 68 weeks) OASIS-4 (oral semaglutide/Wegovy, 64 weeks). For educational comparison only—these are GLP-1/GIP + B6 Dual Weight-Loss

Drowsiness after injection is normal and expected

This delivery method informs lower-dose but more frequent protocols for gastrointestinal use

Combining them with a good diet and regular exercise is key for the best results, and they can be a helpful part of a weight loss plan [f48c]

Pancreatic and Thyroid Risks: While rare, there are concerns about potential risks such as acute pancreatitis, gallbladder disease, and an increased risk of thyroid C-cell tumors (based on animal studies)

Most patients will need to visit our local clinic on a weekly or monthly basis for quick weigh-ins and scheduled medication injections